Skip to content

Resuscitation strategy in obstetric hemorrhage.

Restrictive versus massive fluid resuscitation strategy: Influence on blood loss and hemostatic parameters in obstetric hemorrhage.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22968
Enrollment
250
Registered
2013-01-11
Start date
2013-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post partum hemorrhage, restritive fluid resuscitation, coagulopathy

Interventions

Restrictive fluid resuscitation: standaard care means suppletion of 1,5-2 times the amount of lost blood, in the study group 0,75-1x the amount of blood loss will be administered.

Sponsors

Maastricht Universitair Medisch Centrum
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pregnant women attending the outpatient clinic; 2. Pregnant and delivery/labor, > 24 weeks; 3. Age ≥ 18 years; 4. Informed consent; 5. Mentally competent, understanding Dutch language.

Exclusion criteria

Exclusion criteria: 1. Labor < 24+0 weeks; 2. Prophylactic or therapeutic anticoagulant therapy (carbasalate calcium within the last 10 days or low molecular weight heparins within last 48 hours); 3. Known congenital, coagulation disorders; 4. Pre-eclampsia (higher risk of low plasma volume, higher risk of volume overload).

Design outcomes

Primary

MeasureTime frame
In women with early, mild PPH (blood loss 500-750ml) we would like to establish whether controlled hypotensive resuscitation strategy reduces the progression to severe PPH compared to care as usual.

Secondary

MeasureTime frame
1. To evaluate if controlled hypotensive resuscitation reduces transfusion requirements; 2. To evaluate if controlled hypotensive resuscitation leads to less coagulopathies.

Contacts

Public ContactNatascha Lange, de

Postbus 5800

natascha.de.lange@mumc.nl+31 (0)43 3874800

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)